INN monograph
chlorpheniramine mal 1mg, pseudoephedrine Hcl 15mg., paracetamol 120mg/5ml
Non-opioid analgesic / antipyretic · POM
Review pending · Source: Local active-ingredient clinical extract; Component monographs (multi-source pipeline); Professional class pharmacology (Non-opioid analgesic / antipyretic)
Verify before clinical use
This monograph does not yet include a traceable source link. Confirm dose, contraindications, interactions, and regulatory status against the current SmPC and Kenya STG/EML.
Kenya market
Wholesale / list prices where loaded
Risk first
Contraindications
- [chlorpheniramine mal] Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC.
Precautions
- [From component Chlorpheniramine] Warnings Ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis glaucoma difficulty in urination due to enlargement of the prostate gland
Point of care
Dosing
Adult
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Paediatric
Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.
Renal
Generally safe; prolonged high dose rare associations — prefer careful use in advanced CKD.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic
PRIMARY toxicity organ in overdose; therapeutic doses usually safe if daily limits respected.
Safety
Drug interactions
- Fixed-dose/multi-ingredient product.
- Clinical details partially inherited from component monographs: Chlorpheniramine.
- Confirm combination SmPC for exact dosing.
Safety
Adverse effects
- [From component Chlorpheniramine] Drowsiness
- psychomotor impairment
- anti-muscarinic effects [e.g. urinary retention
- dry mouth
- GI disturbances
- blurred vision]
- allergic reactions
- epileptic form seizure in patients with cerebral cortex focal lesion
- muscle weakness
- tachycardia
- tight chest
- paradoxical CNS stimulation - mostly in children.
Use
Indications
- Therapeutic use is agent- and indication-specific within the class (Non-opioid analgesic / antipyretic).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- Relief of symptoms of cold and flu.
Pharmacology
Mode of action
Combination product.
Full mechanism text
Combination product. Component mechanism (Chlorpheniramine): It acts by competing with histamine for H1-receptor sites on effector cells. Its anticholinergic actions give a drying effect on the nasal mucosa.
ADME
Pharmacokinetics & PD
| Onset | 30–60 minutes oral |
|---|---|
| Duration | 4–6 hours |
| Route | ORAL / RECTAL / IV |
| Metabolism | (glucuronidation/sulfation); toxic NAPQI pathway via CYP2E1 when pathways saturated or glutathione depleted. |
| Half-life | ~2–3 h; prolonged in liver disease/overdose. |
Full PK/PD text
Rapid oral absorption. Hepatic metabolism (glucuronidation/sulfation); toxic NAPQI pathway via CYP2E1 when pathways saturated or glutathione depleted. Half-life ~2–3 h; prolonged in liver disease/overdose.
Kenya
Brands & prices
| Brand | Company | Pack | KES |
|---|---|---|---|
| No brands linked yet. | |||
Special populations
Pregnancy & lactation
Pregnancy
Analgesic/antipyretic of choice in pregnancy when needed; use lowest effective dose/shortest duration.
Lactation
Compatible with breastfeeding at standard doses.
Diet
Food & alcohol
- Food
- Food
Trust
Sources & disclaimer
Source: Local active-ingredient clinical extract; Component monographs (multi-source pipeline); Professional class pharmacology (Non-opioid analgesic / antipyretic)
Clinical review date not recorded.
No traceable source URL is currently attached.
Decision support only — not a substitute for clinical judgment, product SmPC, or Kenya STG/EML.